Evidences for prevention of nitroglycerin tolerance by carvedilol

Pharmacological Research

Volumn 53, Issue 4, 2006, Pages 380-385

  El Demerdash, Ebtehal ^a  

^a African Union Organization St Abbassia   (Egypt)

Author keywords

Carvedilol; Nitroglycerin tolerance; Superoxide anion; Superoxide dismutase and glutathione

Indexed keywords

CARVEDILOL; GLUTATHIONE; GLYCERYL TRINITRATE; OXYGEN; SUPEROXIDE DISMUTASE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; AORTA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG TOLERANCE; EXPERIMENTAL DESIGN; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AORTA, THORACIC; CARBAZOLES; DRUG INTERACTIONS; DRUG RESISTANCE; GLUTATHIONE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NITROGLYCERIN; PROPANOLAMINES; RABBITS; SUPEROXIDE DISMUTASE; SUPEROXIDES; VASODILATOR AGENTS;

EID: 33646483563     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.01.007     Document Type: Article

References (36)

1. Glasser S.P. Prospects for therapy of nitrate tolerance. Lancet 353 (1999) 1545-1546
2. Parker J.D. Nitrate tolerance, oxidative stress and mitochondrial function: another worrisome chapter on the effects of organic nitrates. J Clin Invest 113 (2004) 352-354
3. Dupuis J.G., Lemieux L.R., and Rouleau J.L. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume. Neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 16 (1990) 923-931
4. Packer M., Lee W., Kessler P.D., et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 317 (1987) 799-804
5. Parker J.D., Farrel B., Fenton T., et al. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 84 (1991) 2336-2345
6. Munzel T., Sayegh H., Freeman B.A., et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 95 (1995) 187-194
7. Gori T., and Parker J.D. The puzzle of nitrate tolerance pieces smaller than we thought?. Circulation 106 (2002) 2404-2408
8. Gori T., and Parker J.D. Nitrate tolerance: a unifying hypothesis. Circulation 106 (2002) 2510-2513
9. Bassenge E., Fink N., Skatchkov M., et al. Dietary supplement with Vitamin C prevents nitrate tolerance. J Clin Invest 102 (1998) 67-71
10. Watanabe H., Kakihana M., Ohtsuka S., et al. Randomized double-blind, placebo-controlled study of Vitamin E supplementation on attenuation of development of nitrate tolerance. Circulation 96 (1997) 2545-2550
11. Poole-Wilson P.A., Swedberg K., and Cleland J.G. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 362 (2003) 7-13
12. Stroe A.F., and Gheorghiade M. Carvedilol: β-blockade and beyond. Rev Cardiovasc Med 5 Suppl. 1 (2004) S18-S27
13. Book W.M. Carvedilol: a nonselective beta blocking agent with antioxidant properties. Conest Heart Fail 8 (2002) 173-177
14. Yue T.L., Cheng H.Y., Lysko P.G., et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 263 (1992) 92-98
15. Yue T.L., Mckenna P.J., Gu J.L., et al. Carvedilol, a new hypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension 22 (1993) 922-928
16. Arumanayagam M, Chan S, Tong S, et al. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. J Cardiovasc Pharmacol 200;37:48-54.
17. Watanabe H., Kakihana M.M., Ohtsuka S., et al. Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. J Am Coll Cardiol 32 (1998) 1194-1201
18. Watanabe H., Kakihana M.M., Ohtsuka S., et al. Preventive effects of carvedilol on nitrate tolerance: a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. J Am Coll Cardiol 32 (1998) 1201-1206
19. Wang H.D., Pagano P.J., Du Y., et al. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 82 (1998) 810-818
20. Tietze F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal Biochem 27 (1969) 502-522
21. Oyanagui Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem 142 (1984) 290-296
22. Parker J.D., and Gori T. Tolerance to the organic nitrates: new ideas, new mechanisms. Continued mystery. Circulation 104 (2001) 2263-2265
23. Ma X.L., Yue T.L., Lopez B.L., et al. Carvedilol, a new beta adrenoceptor blocker and free radical scavenger, attenuates myocardial ischemia reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther 277 (1996) 128-136
24. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol 271 (1996) C1424-C1437
25. Fink B., Schwemmer M., Fink N., et al. Tolerance to nitrates with enhanced radical formation suppressed by carvedilol. J Cardiovasc Pharmacol 34 (1999) 800-805
26. Asbrink S., Zickert A., Bratt J., et al. No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of superoxide ions. Biochem Pharmacol 59 (2000) 1007-1013
27. Suzuki Y., Tanaka M., Sohmiya M., et al. Antioxidant properties of carvedilol: inhibition of lipid peroxidation, protein oxidation and superoxide generation. Neurol Res 25 (2003) 749-753
28. Lopez B.L., Christopher T.A., Yue T.L., et al. Carvedilol, a new beta-adrenoceptor blocker antihypertensive drug, protects against free radical-induced endothelial dysfunction. Pharmacology 51 (1995) 165-173
29. Feuerstein G.Z., Shusterman N.H., and Ruffolo J.R.R.R. Carvedilol update IV: prevention of oxidative stress, cardiac remodling and progression of congestive heart failure. Drugs Today 33 (1997) 453-457
30. Feuerstein R., Yue T.L., and Carvedilol. A novel multiple action antihypertensive drug that provides major organ protection. Cardiovasc Drug Rev 12 (1994) 85-103
31. Harrison D.G. Endothelial function and oxidative stress. Clin Cardiol 20 Suppl. II (1997) 11-17
32. Mayer B., Schrammel A., Klatt P., et al. Peroxynitrite-induced accumulation of cyclic GMP in endothelial cells and stimulation of purified soluble guanylyl cyclase: dependence on glutathione and possible role of S-nitrosylation. J Biol Chem 270 (1995) 17355-17360
33. Ma X.L., Lopez B.L., Liu G.-L., et al. Hypercholesterolemia impairs detoxification mechanism against peroxynitrite and renders the vascular tissue more susceptible to oxidative injury. Circ Res 80 (1997) 894-901
34. Lysko P.G., Feuerstein G.Z., and Ruffolo J.R.R.R. Carvedilol: A novel multiple action antihypertensive drug. Pharm News 2 (1995) 12-16
35. Kurz S., Kink U., and Nickenig G. Evidence for a causal role of the rennin-angiotensin system in nitrate tolerance. Circulation 99 (1999) 3181-3187
36. Ariens E.J., and Simonis A.M. Physiological and pharmacological aspects of adrenergic receptor classification. Biochem Pharmacol 32 (1983) 1539-1545